The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 20, 2018
Filed:
Nov. 25, 2015
Ubivac, Llc, Portland, OR (US);
Providence Health & Services-oregon, Portland, OR (US);
Traci Hilton, Portland, OR (US);
Sandra Aung, Solana Beach, CA (US);
Rieneke van de Ven, Den Haang, NL;
Christopher Paustian, Portland, OR (US);
Tarsem Moudgil, Beaverton, OR (US);
Christopher Dubay, Portland, OR (US);
Christopher Twitty, Solana Beach, CA (US);
Hong-Ming Hu, Portland, OR (US);
Bernard A. Fox, Portland, OR (US);
UbiVac, LLC, Portland, OR (US);
Providence Health & Services-Oregon, Portland, OR (US);
Abstract
A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types. In this way, an allogeneic, off-the-shelf cancer vaccine may be produced and made available to be administered in order to stimulate a targeted immune response in patients bearing different tumor types.